Top 8 Pulmonology startups in USA
Jan 08, 2026
|
Like
30
1
Funding: $253M
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
2
Funding: $295.5M
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
3
Funding: $53.9M
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
4
Funding: $23.3M
Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.
Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.
5
Funding: $22M
Telesair creates Respiratory Humidifier, designed for use in the ICU, and support the development of a new product that aims to help patients leave the hospital more quickly and stay at home safely.
Telesair creates Respiratory Humidifier, designed for use in the ICU, and support the development of a new product that aims to help patients leave the hospital more quickly and stay at home safely.
6
Funding: $16.8M
Cohero developed a connected spirometer to assess lung function and medication adherence in asthma and COPD patients. It was designed to be a clinical grade medical device to function as a barometer for lung function. It also produced a patient-facing app that helps users track their data.
Cohero developed a connected spirometer to assess lung function and medication adherence in asthma and COPD patients. It was designed to be a clinical grade medical device to function as a barometer for lung function. It also produced a patient-facing app that helps users track their data.
7
Funding: $15.7M
Sentrian developed a biosensor supported by cloud technology and machine to detect deteriorating health of patients earlier.
Sentrian developed a biosensor supported by cloud technology and machine to detect deteriorating health of patients earlier.
8
Funding: $5M
LifeMap Solutions develops a m-Health platform that integrates disparate sources of information to generate an accurate picture of an individual's health. One of the primary apps is COPD Navigator app.
LifeMap Solutions develops a m-Health platform that integrates disparate sources of information to generate an accurate picture of an individual's health. One of the primary apps is COPD Navigator app.
★
See also:
